Salmonella typhimurium engineered to deliver cancer/testis antigen NY-ESO-1 through type III secretion (S typhimurium-NY-ESO-1) was shown to be an efficient cancer vaccine construct in mice and to stimulate NY-ESO-1-specific CD8+/CD4+ T cells in vitro in patients with cancer with NY-ESO-1 spontaneous immunity. e also showed that individuals without spontaneous immunity to NY-ESO-1 had specific CD4+ T-cell precursors with high avidity to NY-ESO-1 under tight control by CD4+CD25 + regulatory T (Treg) cells. We now found that in healthy donors and patients with melanoma without NY-ESO-1 spontaneous immunity, S typhimurium-NY-ESO-1 elicits CD4+ T helper 1 (Th1) cells in vitro recognizing naturally processed antigen from these high-avidity NY-ESO-1-specific naive precursors. In contrast to peptide stimulation, induction of specific Th1 cells with S typhimurium-NY-ESO-1 did not require in vitro depletion of CD4+CD25+ Treg cells, and this prevailing effect was partially blocked by disruption of interleukin-6 or glucocorticoid-nduced TNF receptor (GITR) signals. Furthermore, S typhimurium-induced Th1 cells had higher GITR expression than peptide-nduced Th1 cells and were resistant to suppression by CD4+CD25+ Treg cells in a GITR-dependent fashion. We propose that S typhimurium-NY-ESO-1 induces antigenspecific T-cell responses that are resistant to suppression by CD4+CD25+ Treg cells. © 2008 by The American Society of Hematology.
CITATION STYLE
Nishikawa, H., Tsuji, T., Jäger, E., Briones, G., Ritter, G., Old, L. J., … Gnjatic, S. (2008). Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood, 111(3), 1404–1412. https://doi.org/10.1182/blood-2007-09-113761
Mendeley helps you to discover research relevant for your work.